How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
Identifieur interne : 002387 ( Istex/Corpus ); précédent : 002386; suivant : 002388How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
Auteurs : E. Tanaka ; N. Kurata ; H. YasuharaSource :
- Journal of Clinical Pharmacy and Therapeutics [ 0269-4727 ] ; 2003-06.
English descriptors
- Teeft :
- Adverse effects, Blackwell publishing, British journal, Caffeine, Chlorzoxazone, Clinical pharmacology, Clinical pharmacy, Cocktail approach, Cortisol, Cyp3a, Cytochrome, Dapsone, Debrisoquine, Dextromethorphan, Drug metabolism, Enzyme phenotyping, Hepatic, Hplc, Hplc hplc, Human cytochrome, Hydroxylation, Mephenytoin, Metabolism, Metabolizing, Midazolam, Multiple probe drugs, Omeprazole, Other hand, Pharmacogenetics, Pharmacology, Phenotype, Phenotyping, Phenotyping method, Phenotyping probes, Plasma ratio, Plasma samples, Probe, Probe drug, Probe drugs, Selective phenotyping method, Simultaneous administration, Sparteine, Tanaka, Therapeutics, Tolbutamide, Urine, Urine metabolite ratio, Urine samples, Vivo, Vivo studies, Xanthine oxidase.
Abstract
Relatively selective in vivo substrate probes have been developed for several major CYP isoforms involved in oxidative drug metabolism. There are basically two in vivo methods for identifying the phenotype. One method, the selective (CYP‐specific) phenotyping method, involves administering one single probe drug, whereas the other is a mixed phenotyping or ‘cocktail’ method involving the simultaneous administration of multiple probe drugs, specific for the individual P450. At present, caffeine and chlorzoxazone are used most often as probe drugs for CYP1A2 and CYP2E1, respectively, but these are not necessarily the best probe drugs. Of the potential probe drugs for CYP2C9, CYP2C19, CYP2D6 and CYP3A4, none is really useful. Despite current limitations, the cocktail method for obtaining information about multiple CYP activities in a single experimental session is likely to be more widely used as a screening or phenotyping method for humans in the future.
Url:
DOI: 10.1046/j.1365-2710.2003.00486.x
Links to Exploration step
ISTEX:57DB5EBEAF56F5D9895376010054E89897264292Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?</title><author><name sortKey="Tanaka, E" sort="Tanaka, E" uniqKey="Tanaka E" first="E." last="Tanaka">E. Tanaka</name><affiliation><mods:affiliation>Institute of Community Medicine, University of Tsukuba, Ibaraki‐ken, Japan and</mods:affiliation></affiliation></author><author><name sortKey="Kurata, N" sort="Kurata, N" uniqKey="Kurata N" first="N." last="Kurata">N. Kurata</name><affiliation><mods:affiliation>School of Medicine, Showa University, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Yasuhara, H" sort="Yasuhara, H" uniqKey="Yasuhara H" first="H." last="Yasuhara">H. Yasuhara</name><affiliation><mods:affiliation>School of Medicine, Showa University, Tokyo, Japan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:57DB5EBEAF56F5D9895376010054E89897264292</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1046/j.1365-2710.2003.00486.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-LXBFBDF7-9/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002387</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002387</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?</title><author><name sortKey="Tanaka, E" sort="Tanaka, E" uniqKey="Tanaka E" first="E." last="Tanaka">E. Tanaka</name><affiliation><mods:affiliation>Institute of Community Medicine, University of Tsukuba, Ibaraki‐ken, Japan and</mods:affiliation></affiliation></author><author><name sortKey="Kurata, N" sort="Kurata, N" uniqKey="Kurata N" first="N." last="Kurata">N. Kurata</name><affiliation><mods:affiliation>School of Medicine, Showa University, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Yasuhara, H" sort="Yasuhara, H" uniqKey="Yasuhara H" first="H." last="Yasuhara">H. Yasuhara</name><affiliation><mods:affiliation>School of Medicine, Showa University, Tokyo, Japan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Clinical Pharmacy and Therapeutics</title><title level="j" type="alt">JOURNAL OF CLINICAL PHARMACY THERAPEUTICS</title><idno type="ISSN">0269-4727</idno><idno type="eISSN">1365-2710</idno><imprint><biblScope unit="vol">28</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="157">157</biblScope><biblScope unit="page" to="165">165</biblScope><biblScope unit="page-count">9</biblScope><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2003-06">2003-06</date></imprint><idno type="ISSN">0269-4727</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0269-4727</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adverse effects</term><term>Blackwell publishing</term><term>British journal</term><term>Caffeine</term><term>Chlorzoxazone</term><term>Clinical pharmacology</term><term>Clinical pharmacy</term><term>Cocktail approach</term><term>Cortisol</term><term>Cyp3a</term><term>Cytochrome</term><term>Dapsone</term><term>Debrisoquine</term><term>Dextromethorphan</term><term>Drug metabolism</term><term>Enzyme phenotyping</term><term>Hepatic</term><term>Hplc</term><term>Hplc hplc</term><term>Human cytochrome</term><term>Hydroxylation</term><term>Mephenytoin</term><term>Metabolism</term><term>Metabolizing</term><term>Midazolam</term><term>Multiple probe drugs</term><term>Omeprazole</term><term>Other hand</term><term>Pharmacogenetics</term><term>Pharmacology</term><term>Phenotype</term><term>Phenotyping</term><term>Phenotyping method</term><term>Phenotyping probes</term><term>Plasma ratio</term><term>Plasma samples</term><term>Probe</term><term>Probe drug</term><term>Probe drugs</term><term>Selective phenotyping method</term><term>Simultaneous administration</term><term>Sparteine</term><term>Tanaka</term><term>Therapeutics</term><term>Tolbutamide</term><term>Urine</term><term>Urine metabolite ratio</term><term>Urine samples</term><term>Vivo</term><term>Vivo studies</term><term>Xanthine oxidase</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Relatively selective in vivo substrate probes have been developed for several major CYP isoforms involved in oxidative drug metabolism. There are basically two in vivo methods for identifying the phenotype. One method, the selective (CYP‐specific) phenotyping method, involves administering one single probe drug, whereas the other is a mixed phenotyping or ‘cocktail’ method involving the simultaneous administration of multiple probe drugs, specific for the individual P450. At present, caffeine and chlorzoxazone are used most often as probe drugs for CYP1A2 and CYP2E1, respectively, but these are not necessarily the best probe drugs. Of the potential probe drugs for CYP2C9, CYP2C19, CYP2D6 and CYP3A4, none is really useful. Despite current limitations, the cocktail method for obtaining information about multiple CYP activities in a single experimental session is likely to be more widely used as a screening or phenotyping method for humans in the future.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>phenotyping</json:string><json:string>therapeutics</json:string><json:string>pharmacology</json:string><json:string>caffeine</json:string><json:string>hplc</json:string><json:string>clinical pharmacology</json:string><json:string>cytochrome</json:string><json:string>dextromethorphan</json:string><json:string>chlorzoxazone</json:string><json:string>cyp3a</json:string><json:string>mephenytoin</json:string><json:string>midazolam</json:string><json:string>hepatic</json:string><json:string>debrisoquine</json:string><json:string>omeprazole</json:string><json:string>dapsone</json:string><json:string>tanaka</json:string><json:string>pharmacogenetics</json:string><json:string>urine</json:string><json:string>cocktail approach</json:string><json:string>probe drugs</json:string><json:string>clinical pharmacy</json:string><json:string>urine metabolite ratio</json:string><json:string>blackwell publishing</json:string><json:string>phenotype</json:string><json:string>cortisol</json:string><json:string>tolbutamide</json:string><json:string>probe drug</json:string><json:string>metabolizing</json:string><json:string>phenotyping probes</json:string><json:string>sparteine</json:string><json:string>drug metabolism</json:string><json:string>british journal</json:string><json:string>metabolism</json:string><json:string>phenotyping method</json:string><json:string>plasma ratio</json:string><json:string>probe</json:string><json:string>xanthine oxidase</json:string><json:string>enzyme phenotyping</json:string><json:string>urine samples</json:string><json:string>adverse effects</json:string><json:string>other hand</json:string><json:string>vivo studies</json:string><json:string>hydroxylation</json:string><json:string>selective phenotyping method</json:string><json:string>multiple probe drugs</json:string><json:string>simultaneous administration</json:string><json:string>human cytochrome</json:string><json:string>plasma samples</json:string><json:string>hplc hplc</json:string><json:string>vivo</json:string></teeft></keywords><author><json:item><name>E. Tanaka</name><affiliations><json:string>Institute of Community Medicine, University of Tsukuba, Ibaraki‐ken, Japan and</json:string></affiliations></json:item><json:item><name>N. Kurata</name><affiliations><json:string>School of Medicine, Showa University, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>H. Yasuhara</name><affiliations><json:string>School of Medicine, Showa University, Tokyo, Japan</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>cytochrome P450</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>drug metabolism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>polymorphism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>probes</value></json:item></subject><articleId><json:string>JCPT486</json:string></articleId><arkIstex>ark:/67375/WNG-LXBFBDF7-9</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>Relatively selective in vivo substrate probes have been developed for several major CYP isoforms involved in oxidative drug metabolism. There are basically two in vivo methods for identifying the phenotype. One method, the selective (CYP‐specific) phenotyping method, involves administering one single probe drug, whereas the other is a mixed phenotyping or ‘cocktail’ method involving the simultaneous administration of multiple probe drugs, specific for the individual P450. At present, caffeine and chlorzoxazone are used most often as probe drugs for CYP1A2 and CYP2E1, respectively, but these are not necessarily the best probe drugs. Of the potential probe drugs for CYP2C9, CYP2C19, CYP2D6 and CYP3A4, none is really useful. Despite current limitations, the cocktail method for obtaining information about multiple CYP activities in a single experimental session is likely to be more widely used as a screening or phenotyping method for humans in the future.</abstract><qualityIndicators><score>7.837</score><pdfWordCount>4121</pdfWordCount><pdfCharCount>29203</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>9</pdfPageCount><pdfPageSize>595 x 782 pts</pdfPageSize><pdfWordsPerPage>458</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>143</abstractWordCount><abstractCharCount>965</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?</title><pmid><json:string>12795773</json:string></pmid><genre><json:string>review-article</json:string></genre><host><title>Journal of Clinical Pharmacy and Therapeutics</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1365-2710</json:string></doi><issn><json:string>0269-4727</json:string></issn><eissn><json:string>1365-2710</json:string></eissn><publisherId><json:string>JCPT</json:string></publisherId><volume>28</volume><issue>3</issue><pages><first>157</first><last>165</last><total>9</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1970s</json:string><json:string>2003</json:string><json:string>1980s</json:string></date><geogName></geogName><orgName><json:string>Reference Specimen Instrument</json:string><json:string>Japan and School of Medicine, Showa University, Tokyo, Japan SUMMARY Relatively</json:string><json:string>Blackwell Publishing Ltd</json:string><json:string>Institute of Community Medicine, University of Tsukuba, Tsukuba</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>H. Yasuhara</json:string><json:string>Einosuke Tanaka</json:string><json:string>Caffeine Omeprazole</json:string><json:string>In</json:string><json:string>N. Kurata</json:string></persName><placeName><json:string>Pittsburgh</json:string><json:string>Cooperstown</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Ozdemir et al.</json:string><json:string>Kashuba et al.</json:string><json:string>May et al.</json:string><json:string>Tenneze et al.</json:string><json:string>Schellens et al.</json:string><json:string>Streetman et al.</json:string><json:string>Damkier et al.</json:string><json:string>Frye et al.</json:string><json:string>E. Tanaka et al.</json:string><json:string>Adedoyin et al.</json:string><json:string>Dierks et al.</json:string><json:string>Brynne et al.</json:string><json:string>Zhu et al.</json:string><json:string>Mishin et al.</json:string><json:string>Zaigler et al.</json:string><json:string>Kivisto et al.</json:string><json:string>Change et al.</json:string><json:string>Eap et al.</json:string><json:string>Palmer et al.</json:string><json:string>Pharmacy and Therapeutics (2003)</json:string><json:string>Balian et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-LXBFBDF7-9</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pharmacology & pharmacy</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - pharmacology & pharmacy</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Pharmacology (medical)</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string><json:string>3 - Pharmacology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2003</publicationDate><copyrightDate>2003</copyrightDate><doi><json:string>10.1046/j.1365-2710.2003.00486.x</json:string></doi><id>57DB5EBEAF56F5D9895376010054E89897264292</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-LXBFBDF7-9/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-LXBFBDF7-9/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-LXBFBDF7-9/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?</title><title level="a" type="short">Cytochrome P450 phenotyping probes</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2003-06"></date></publicationStmt><notesStmt><note type="content-type" subtype="review-article" source="reviewArticle" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="review-article"><analytic><title level="a" type="main">How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?</title><title level="a" type="short">Cytochrome P450 phenotyping probes</title><author xml:id="author-0000"><persName><forename type="first">E.</forename><surname>Tanaka</surname></persName><affiliation><orgName type="institution">Institute of Community Medicine</orgName><orgName type="institution">University of Tsukuba</orgName><address><addrLine>Ibaraki‐ken</addrLine><addrLine>Japan and</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">N.</forename><surname>Kurata</surname></persName><affiliation><orgName type="department">School of Medicine</orgName><orgName type="institution">Showa University</orgName><address><addrLine>Tokyo</addrLine><addrLine>Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">H.</forename><surname>Yasuhara</surname></persName><affiliation><orgName type="department">School of Medicine</orgName><orgName type="institution">Showa University</orgName><address><addrLine>Tokyo</addrLine><addrLine>Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><idno type="istex">57DB5EBEAF56F5D9895376010054E89897264292</idno><idno type="ark">ark:/67375/WNG-LXBFBDF7-9</idno><idno type="DOI">10.1046/j.1365-2710.2003.00486.x</idno><idno type="unit">JCPT486</idno><idno type="toTypesetVersion">file:JCPT.JCPT486.pdf</idno></analytic><monogr><title level="j" type="main">Journal of Clinical Pharmacy and Therapeutics</title><title level="j" type="alt">JOURNAL OF CLINICAL PHARMACY THERAPEUTICS</title><idno type="pISSN">0269-4727</idno><idno type="eISSN">1365-2710</idno><idno type="book-DOI">10.1111/(ISSN)1365-2710</idno><idno type="book-part-DOI">10.1111/jcp.2003.28.issue-3</idno><idno type="product">JCPT</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">28</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="157">157</biblScope><biblScope unit="page" to="165">165</biblScope><biblScope unit="page-count">9</biblScope><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2003-06"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Summary</head><p>Relatively selective <hi rend="italic">in vivo</hi> substrate probes have been developed for several major CYP isoforms involved in oxidative drug metabolism. There are basically two <hi rend="italic">in vivo</hi> methods for identifying the phenotype. One method, the selective (CYP‐specific) phenotyping method, involves administering one single probe drug, whereas the other is a mixed phenotyping or ‘cocktail’ method involving the simultaneous administration of multiple probe drugs, specific for the individual P450. At present, caffeine and chlorzoxazone are used most often as probe drugs for CYP1A2 and CYP2E1, respectively, but these are not necessarily the best probe drugs. Of the potential probe drugs for CYP2C9, CYP2C19, CYP2D6 and CYP3A4, none is really useful. Despite current limitations, the cocktail method for obtaining information about multiple CYP activities in a single experimental session is likely to be more widely used as a screening or phenotyping method for humans in the future.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">cytochrome P450</term><term xml:id="k2">drug metabolism</term><term xml:id="k3">polymorphism</term><term xml:id="k4">probes</term></keywords><keywords rend="tocHeading1"><term>Review Articles</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-LXBFBDF7-9/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Science Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1365-2710</doi><issn type="print">0269-4727</issn><issn type="electronic">1365-2710</issn><idGroup><id type="product" value="JCPT"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="JOURNAL OF CLINICAL PHARMACY THERAPEUTICS">Journal of Clinical Pharmacy and Therapeutics</title></titleGroup></publicationMeta><publicationMeta level="part" position="06003"><doi origin="wiley">10.1111/jcp.2003.28.issue-3</doi><numberingGroup><numbering type="journalVolume" number="28">28</numbering><numbering type="journalIssue" number="3">3</numbering></numberingGroup><coverDate startDate="2003-06">June 2003</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="0015700" status="forIssue"><doi origin="wiley">10.1046/j.1365-2710.2003.00486.x</doi><idGroup><id type="unit" value="JCPT486"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="tocHeading1">Review Articles</title></titleGroup><eventGroup><event type="firstOnline" date="2003-06-10"></event><event type="publishedOnlineFinalForm" date="2003-06-10"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.5 mode:FullText source:FullText result:FullText" date="2010-04-07"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-30"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-24"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="157">157</numbering><numbering type="pageLast" number="165">165</numbering></numberingGroup><correspondenceTo>Dr Einosuke Tanaka, Institute of Community Medicine, University of Tsukuba, Tsukuba‐shi, Ibaraki‐ken 305‐8575, Japan. Tel./Fax: +81 29 853 3057; e‐mail: <email>einosuke@md.tsukuba.ac.jp</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:JCPT.JCPT486.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 27 May 2002, Accepted 11 April 2003</unparsedEditorialHistory><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count></countGroup><titleGroup><title type="main">How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes <i>in vivo</i>?</title><title type="shortAuthors"><i>E. Tanaka</i> et al.</title><title type="short"><i>Cytochrome P450 phenotyping probes</i></title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>E.</givenNames><familyName>Tanaka</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>N.</givenNames><familyName>Kurata</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a2"><personName><givenNames>H.</givenNames><familyName>Yasuhara</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="JP"><unparsedAffiliation>Institute of Community Medicine, University of Tsukuba, Ibaraki‐ken, Japan and</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="JP"><unparsedAffiliation>School of Medicine, Showa University, Tokyo, Japan</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">cytochrome P450</keyword><keyword xml:id="k2">drug metabolism</keyword><keyword xml:id="k3">polymorphism</keyword><keyword xml:id="k4">probes</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Summary</title><p>Relatively selective <i>in vivo</i> substrate probes have been developed for several major CYP isoforms involved in oxidative drug metabolism. There are basically two <i>in vivo</i> methods for identifying the phenotype. One method, the selective (CYP‐specific) phenotyping method, involves administering one single probe drug, whereas the other is a mixed phenotyping or ‘cocktail’ method involving the simultaneous administration of multiple probe drugs, specific for the individual P450. At present, caffeine and chlorzoxazone are used most often as probe drugs for CYP1A2 and CYP2E1, respectively, but these are not necessarily the best probe drugs. Of the potential probe drugs for CYP2C9, CYP2C19, CYP2D6 and CYP3A4, none is really useful. Despite current limitations, the cocktail method for obtaining information about multiple CYP activities in a single experimental session is likely to be more widely used as a screening or phenotyping method for humans in the future.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Cytochrome P450 phenotyping probes</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?</title></titleInfo><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Tanaka</namePart><affiliation>Institute of Community Medicine, University of Tsukuba, Ibaraki‐ken, Japan and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Kurata</namePart><affiliation>School of Medicine, Showa University, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Yasuhara</namePart><affiliation>School of Medicine, Showa University, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>Blackwell Science Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2003-06</dateIssued><edition>Received 27 May 2002, Accepted 11 April 2003</edition><copyrightDate encoding="w3cdtf">2003</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">2</extent></physicalDescription><abstract lang="en">Relatively selective in vivo substrate probes have been developed for several major CYP isoforms involved in oxidative drug metabolism. There are basically two in vivo methods for identifying the phenotype. One method, the selective (CYP‐specific) phenotyping method, involves administering one single probe drug, whereas the other is a mixed phenotyping or ‘cocktail’ method involving the simultaneous administration of multiple probe drugs, specific for the individual P450. At present, caffeine and chlorzoxazone are used most often as probe drugs for CYP1A2 and CYP2E1, respectively, but these are not necessarily the best probe drugs. Of the potential probe drugs for CYP2C9, CYP2C19, CYP2D6 and CYP3A4, none is really useful. Despite current limitations, the cocktail method for obtaining information about multiple CYP activities in a single experimental session is likely to be more widely used as a screening or phenotyping method for humans in the future.</abstract><subject lang="en"><genre>keywords</genre><topic>cytochrome P450</topic><topic>drug metabolism</topic><topic>polymorphism</topic><topic>probes</topic></subject><relatedItem type="host"><titleInfo><title>Journal of Clinical Pharmacy and Therapeutics</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0269-4727</identifier><identifier type="eISSN">1365-2710</identifier><identifier type="DOI">10.1111/(ISSN)1365-2710</identifier><identifier type="PublisherID">JCPT</identifier><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>157</start><end>165</end><total>9</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Use of probe drugs as predictors of drug metabolism in humans</title></titleInfo><name type="personal"><namePart type="given">KT</namePart><namePart type="family">Kivisto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HK</namePart><namePart type="family">Kroemer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kivisto KT, Kroemer HK (1997) Use of probe drugs as predictors of drug metabolism in humans. Journal of Clinical Pharmacology, 37 (1 Suppl.), 40S–48S.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><detail type="issue"><caption>no.</caption><number>1 Suppl.</number></detail><extent unit="pages"><start>40S</start><end>48S</end></extent></part><relatedItem type="host"><titleInfo><title>Journal of Clinical Pharmacology</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><detail type="issue"><caption>no.</caption><number>1 Suppl.</number></detail><extent unit="pages"><start>40S</start><end>48S</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Problems and perspectives of phenotyping for drug‐metabolizing enzymes in man</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Zaigler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Tantcheva‐Poor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U</namePart><namePart type="family">Fuhr</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zaigler M, Tantcheva‐Poor I, Fuhr U (2000) Problems and perspectives of phenotyping for drug‐metabolizing enzymes in man. International Journal of Clinical Pharmacology and Therapeutics, 38, 1–9.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>1</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>International Journal of Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>1</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Phenotyping of drug‐metabolizing enzymes in adults: a review of in‐vivo cytochrome P450 phenotyping probes</title></titleInfo><name type="personal"><namePart type="given">DS</namePart><namePart type="family">Streetman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Bertino Jr</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AN</namePart><namePart type="family">Nafziger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Streetman DS, Bertino JS Jr, Nafziger AN (2000) Phenotyping of drug‐metabolizing enzymes in adults: a review of in‐vivo cytochrome P450 phenotyping probes. Pharmacogenetics, 10, 187–216.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>187</start><end>216</end></extent></part><relatedItem type="host"><titleInfo><title>Pharmacogenetics</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>187</start><end>216</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>In vivo function tests of hepatic drug‐oxidizing capacity in patients with liver disease</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Tanaka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DD</namePart><namePart type="family">Breimer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tanaka E, Breimer DD (1997) In vivo function tests of hepatic drug‐oxidizing capacity in patients with liver disease. Journal of Clinical Pharmacology and Therapeutics, 22, 237–249.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>237</start><end>249</end></extent></part><relatedItem type="host"><titleInfo><title>Journal of Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>237</start><end>249</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Clinical importance of non‐genetic and genetic cytochrome P450 function tests in liver disease</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Tanaka</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tanaka E (1998) Clinical importance of non‐genetic and genetic cytochrome P450 function tests in liver disease. Journal of Clinical Pharmacology and Therapeutics, 23, 161–170.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>161</start><end>170</end></extent></part><relatedItem type="host"><titleInfo><title>Journal of Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>161</start><end>170</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Validation of the five‐drug ‘Pittsburgh cocktail’ approach for assessment of selective regulation of drug‐metabolizing enzymes</title></titleInfo><name type="personal"><namePart type="given">RF</namePart><namePart type="family">Frye</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GR</namePart><namePart type="family">Matzke</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Adedoyin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Porter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Branch</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA (1997) Validation of the five‐drug ‘Pittsburgh cocktail’ approach for assessment of selective regulation of drug‐metabolizing enzymes. Clinical Pharmacology and Therapeutics, 62, 365–376.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>365</start><end>376</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>365</start><end>376</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Adedoyin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RF</namePart><namePart type="family">Frye</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Mauro</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Branch</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Adedoyin A, Frye RF, Mauro K, Branch RA (1998) Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail. British Journal of Clinical Pharmacology, 46, 215–219.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>215</start><end>219</end></extent></part><relatedItem type="host"><titleInfo><title>British Journal of Clinical Pharmacology</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>215</start><end>219</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping</title></titleInfo><name type="personal"><namePart type="given">AD</namePart><namePart type="family">Kashuba</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AN</namePart><namePart type="family">Nafziger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GL</namePart><namePart type="family">Kearns</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kashuba AD, Nafziger AN, Kearns GL et al. (1998) Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clinical Pharmacology and Therapeutics, 64, 257–268.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>257</start><end>268</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>257</start><end>268</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Brynne</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Bottiger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Hallen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Bertilsson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brynne N, Bottiger Y, Hallen B, Bertilsson L (1999) Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. British Journal of Clinical Pharmacology, 47, 145–150.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>145</start><end>150</end></extent></part><relatedItem type="host"><titleInfo><title>British Journal of Clinical Pharmacology</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>145</start><end>150</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Tenneze</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Verstuyft</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Becquemont</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Poirier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GR</namePart><namePart type="family">Wilkinson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Funck‐Brentano</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tenneze L, Verstuyft C, Becquemont L, Poirier JM, Wilkinson GR, Funck‐Brentano C (1999) Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. Clinical Pharmacology and Therapeutics, 66, 582–588.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>582</start><end>588</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>582</start><end>588</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Damkier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LL</namePart><namePart type="family">Hansen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Brosen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Damkier P, Hansen LL, Brosen K (1999) Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. British Journal of Clinical Pharmacology, 48, 829–838.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>829</start><end>838</end></extent></part><relatedItem type="host"><titleInfo><title>British Journal of Clinical Pharmacology</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>829</start><end>838</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe‐based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Damkier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Brosen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Damkier P, Brosen K (2000) Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe‐based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Clinical Pharmacology and Therapeutics, 68, 199–209.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>199</start><end>209</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>199</start><end>209</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N‐acetyltransferase‐2, and xanthine oxidase with the ‘Cooperstown cocktail’</title></titleInfo><name type="personal"><namePart type="given">DS</namePart><namePart type="family">Streetman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JF</namePart><namePart type="family">Bleakley</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Kim</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Streetman DS, Bleakley JF, Kim JS et al. (2000) Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N‐acetyltransferase‐2, and xanthine oxidase with the ‘Cooperstown cocktail’. Clinical Pharmacology and Therapeutics, 68, 375–383.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>375</start><end>383</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>375</start><end>383</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A)</title></titleInfo><name type="personal"><namePart type="given">JL</namePart><namePart type="family">Palmer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RJ</namePart><namePart type="family">Scott</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Gibson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Dickins</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Pleasance</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Palmer JL, Scott RJ, Gibson A, Dickins M, Pleasance S (2001) An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). British Journal of Clinical Pharmacology, 52, 555–561.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>555</start><end>561</end></extent></part><relatedItem type="host"><titleInfo><title>British Journal of Clinical Pharmacology</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>555</start><end>561</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test</title></titleInfo><name type="personal"><namePart type="given">CB</namePart><namePart type="family">Eap</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Bondolfi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Zullino</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Eap CB, Bondolfi G, Zullino D et al. (2001) Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Therapeutic Drug Monitoring, 23, 228–231.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>228</start><end>231</end></extent></part><relatedItem type="host"><titleInfo><title>Therapeutic Drug Monitoring</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>228</start><end>231</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Assessment of cytochrome P450 activity by a five‐drug cocktail approach</title></titleInfo><name type="personal"><namePart type="given">B</namePart><namePart type="family">Zhu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DS</namePart><namePart type="family">Ou‐Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">XP</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SL</namePart><namePart type="family">Huang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ZR</namePart><namePart type="family">Tan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">He</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HH</namePart><namePart type="family">Zhou</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhu B, Ou‐Yang DS, Chen XP, Huang SL, Tan ZR, He N, Zhou HH (2001) Assessment of cytochrome P450 activity by a five‐drug cocktail approach. Clinical Pharmacology and Therapeutics, 70, 455–461.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>455</start><end>461</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>455</start><end>461</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>A ‘cocktail’ strategy to assess in vivo oxidative drug metabolism in humans</title></titleInfo><name type="personal"><namePart type="given">DD</namePart><namePart type="family">Breimer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JH</namePart><namePart type="family">Schellens</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Breimer DD, Schellens JH (1990) A ‘cocktail’ strategy to assess in vivo oxidative drug metabolism in humans. Trends in Pharmacological Sciences, 11, 223–225.</note><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>223</start><end>225</end></extent></part><relatedItem type="host"><titleInfo><title>Trends in Pharmacological Sciences</title></titleInfo><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>223</start><end>225</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Rostami‐Hodjegan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Nurminen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PR</namePart><namePart type="family">Jackson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GT</namePart><namePart type="family">Tucker</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rostami‐Hodjegan A, Nurminen S, Jackson PR, Tucker GT (1996) Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics, 6, 121–149.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>121</start><end>149</end></extent></part><relatedItem type="host"><titleInfo><title>Pharmacogenetics</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>121</start><end>149</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>The use of caffeine for enzyme assays: a critical appraisal</title></titleInfo><name type="personal"><namePart type="given">W</namePart><namePart type="family">Kalow</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BK</namePart><namePart type="family">Tang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kalow W, Tang BK (1993) The use of caffeine for enzyme assays: a critical appraisal. Clinical Pharmacology and Therapeutics, 53, 503–514.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>503</start><end>514</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>503</start><end>514</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Five caffeine metabolite ratios to measure tobacco‐induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow</title></titleInfo><name type="personal"><namePart type="given">B</namePart><namePart type="family">Sinues</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Saenz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Lanuza</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ML</namePart><namePart type="family">Bernal</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Fanlo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JL</namePart><namePart type="family">Juste</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Mayayo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sinues B, Saenz MA, Lanuza J, Bernal ML, Fanlo A, Juste JL, Mayayo E (1999) Five caffeine metabolite ratios to measure tobacco‐induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Cancer Epidemiology, Biomarkers & Prevention, 8, 159–166.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>159</start><end>166</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer Epidemiology, Biomarkers & Prevention</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>159</start><end>166</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Variability in caffeine metabolism</title></titleInfo><name type="personal"><namePart type="given">DM</namePart><namePart type="family">Grant</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BK</namePart><namePart type="family">Tang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Kalow</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grant DM, Tang BK, Kalow W (1983) Variability in caffeine metabolism. Clinical Pharmacology and Therapeutics, 33, 591–602.</note><part><date>1983</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>591</start><end>602</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1983</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>591</start><end>602</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon‐inducible cytochrome(s) P‐450 in human liver microsomes</title></titleInfo><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Campbell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DM</namePart><namePart type="family">Grant</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Inaba</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Kalow</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Campbell ME, Grant DM, Inaba T, Kalow W (1987) Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon‐inducible cytochrome(s) P‐450 in human liver microsomes. Drug Metabolism and Disposition, 15, 237–249.</note><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>237</start><end>249</end></extent></part><relatedItem type="host"><titleInfo><title>Drug Metabolism and Disposition</title></titleInfo><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>237</start><end>249</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N‐acetyltransferase activity in humans</title></titleInfo><name type="personal"><namePart type="given">BB</namePart><namePart type="family">Rasmussen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Brosen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rasmussen BB, Brosen K (1996) Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N‐acetyltransferase activity in humans. Therapeutic Drug Monitoring, 18, 254–262.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>254</start><end>262</end></extent></part><relatedItem type="host"><titleInfo><title>Therapeutic Drug Monitoring</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>254</start><end>262</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Tanaka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Ishikawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Yamamoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tanaka E, Ishikawa A, Yamamoto Y et al. (1992) A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites. International Journal of Clinical Pharmacology, Therapeutics and Toxicology, 30, 336–341.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>336</start><end>341</end></extent></part><relatedItem type="host"><titleInfo><title>International Journal of Clinical Pharmacology, Therapeutics and Toxicology</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>336</start><end>341</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>Comparison of hepatic drug‐oxidizing activity after simultaneous administration of two probe drugs, caffeine and trimethadione, to human subjects</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Tanaka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Ishikawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Yamamoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Osada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Tsuji</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Fukao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Iwasaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tanaka E, Ishikawa A, Yamamoto Y, Osada A, Tsuji K, Fukao K, Iwasaki Y (1993) Comparison of hepatic drug‐oxidizing activity after simultaneous administration of two probe drugs, caffeine and trimethadione, to human subjects. Pharmacology & Toxicology, 72, 31–33.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>31</start><end>33</end></extent></part><relatedItem type="host"><titleInfo><title>Pharmacology & Toxicology</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>31</start><end>33</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9</title></titleInfo><name type="personal"><namePart type="given">JO</namePart><namePart type="family">Miners</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Birkett</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Miners JO, Birkett DJ (1996) Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods in Enzymology, 272, 139–145.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>272</number></detail><extent unit="pages"><start>139</start><end>145</end></extent></part><relatedItem type="host"><titleInfo><title>Methods in Enzymology</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>272</number></detail><extent unit="pages"><start>139</start><end>145</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S‐mephenytoin hydroxylation phenotype and CYP2C19 genotype</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Chang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ML</namePart><namePart type="family">Dahl</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Tybring</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Gotharson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Bertilsson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S‐mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics. 5, 358–363.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>358</start><end>363</end></extent></part><relatedItem type="host"><titleInfo><title>Pharmacogenetics.</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>358</start><end>363</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S‐mephenytoin, and omeprazole hydroxylations</title></titleInfo><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Lasker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MR</namePart><namePart type="family">Wester</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Aramsombatdee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JL</namePart><namePart type="family">Raucy</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lasker JM, Wester MR, Aramsombatdee E, Raucy JL (1998) Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S‐mephenytoin, and omeprazole hydroxylations. Archives of Biochemistry and Biophysics, 353, 16–28.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>16</start><end>28</end></extent></part><relatedItem type="host"><titleInfo><title>Archives of Biochemistry and Biophysics</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>16</start><end>28</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit29"><titleInfo><title>Evidence that CYP2C19 is the major (S)‐mephenytoin 4’‐hydroxylase in humans</title></titleInfo><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Goldstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MB</namePart><namePart type="family">Faletto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Romkes‐Sparks</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goldstein JA, Faletto MB, Romkes‐Sparks M et al. (1994) Evidence that CYP2C19 is the major (S)‐mephenytoin 4’‐hydroxylase in humans. Biochemistry, 33, 1743–1752.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>1743</start><end>1752</end></extent></part><relatedItem type="host"><titleInfo><title>Biochemistry</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>1743</start><end>1752</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit30"><titleInfo><title>Limitation to the use of the urinary S‐/R‐mephenytoin ratio in pharmacogenetic studies</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Blouin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PJ</namePart><namePart type="family">McNamara</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Steinmetz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PJ</namePart><namePart type="family">Wedlund</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ (1991) Limitation to the use of the urinary S‐/R‐mephenytoin ratio in pharmacogenetic studies. British Journal of Clinical Pharmacology, 31, 350–352.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>350</start><end>352</end></extent></part><relatedItem type="host"><titleInfo><title>British Journal of Clinical Pharmacology</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>350</start><end>352</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit31"><titleInfo><title>Lung cancer risk in relation to mephenytoin hydroxylation activity</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Benhamou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Bouchardy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Dayer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Benhamou S, Bouchardy C, Dayer P (1997) Lung cancer risk in relation to mephenytoin hydroxylation activity. Pharmacogenetics, 7, 157–159.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>157</start><end>159</end></extent></part><relatedItem type="host"><titleInfo><title>Pharmacogenetics</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>157</start><end>159</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit32"><titleInfo><title>Mephenytoin: a reappraisal</title></titleInfo><name type="personal"><namePart type="given">AS</namePart><namePart type="family">Troupin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LM</namePart><namePart type="family">Ojemann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CB</namePart><namePart type="family">Dodrill</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Troupin AS, Ojemann LM, Dodrill CB (1976) Mephenytoin: a reappraisal. Epilepsia, 17, 403–414.</note><part><date>1976</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>403</start><end>414</end></extent></part><relatedItem type="host"><titleInfo><title>Epilepsia</title></titleInfo><part><date>1976</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>403</start><end>414</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit33"><titleInfo><title>S‐mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin</title></titleInfo><name type="personal"><namePart type="given">EJ</namePart><namePart type="family">Sanz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Villen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Alm</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Bertilsson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sanz EJ, Villen T, Alm C, Bertilsson L (1989) S‐mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clinical Pharmacology and Therapeutics, 45, 495–499.</note><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>495</start><end>499</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>495</start><end>499</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit34"><titleInfo><title>Pharmacogenetic association between the formation of 4‐hydroxymephenytoin and a new metabolite of S‐mephenytoin in man</title></titleInfo><name type="personal"><namePart type="given">PJ</namePart><namePart type="family">Wedlund</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BJ</namePart><namePart type="family">Sweetman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GR</namePart><namePart type="family">Wilkinson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Branch</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wedlund PJ, Sweetman BJ, Wilkinson GR, Branch RA (1987) Pharmacogenetic association between the formation of 4‐hydroxymephenytoin and a new metabolite of S‐mephenytoin in man. Drug Metabolism and Disposition, 15, 277–279.</note><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>277</start><end>279</end></extent></part><relatedItem type="host"><titleInfo><title>Drug Metabolism and Disposition</title></titleInfo><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>277</start><end>279</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit35"><titleInfo><title>Phenotyping of CYP2C19 with enantiospecific HPLC‐quantification of R‐ and S‐mephenytoin and comparison with the intron4/exon5 G–A‐splice site mutation</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Brockmoller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KL</namePart><namePart type="family">Rost</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Gross</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Schenkel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Roots</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brockmoller J, Rost KL, Gross D, Schenkel A, Roots I (1995) Phenotyping of CYP2C19 with enantiospecific HPLC‐quantification of R‐ and S‐mephenytoin and comparison with the intron4/exon5 G–A‐splice site mutation. Pharmacogenetics, 5, 80–88.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>80</start><end>88</end></extent></part><relatedItem type="host"><titleInfo><title>Pharmacogenetics</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>80</start><end>88</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit36"><titleInfo><title>The hydroxylation of omeprazole correlates with S‐mephenytoin metabolism: a population study</title></titleInfo><name type="personal"><namePart type="given">JD</namePart><namePart type="family">Balian</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Sukhova</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JW</namePart><namePart type="family">Harris</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Balian JD, Sukhova N, Harris JW et al. (1995) The hydroxylation of omeprazole correlates with S‐mephenytoin metabolism: a population study. Clinical Pharmacology and Therapeutics, 57, 662–669.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>662</start><end>669</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>662</start><end>669</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit37"><titleInfo><title>The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans</title></titleInfo><name type="personal"><namePart type="given">DA</namePart><namePart type="family">Capon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Bochner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Kerry</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Mikus</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Danz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AA</namePart><namePart type="family">Somogyi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA (1996) The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clinical Pharmacology and Therapeutics, 60, 295–307.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>295</start><end>307</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>295</start><end>307</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit38"><titleInfo><title>Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Schadel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Wu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SV</namePart><namePart type="family">Otton</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Kalow</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EM</namePart><namePart type="family">Sellers</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schadel M, Wu D, Otton SV, Kalow W, Sellers EM (1995) Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. Journal of Clinical Psychopharmacology, 15, 263–269.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>263</start><end>269</end></extent></part><relatedItem type="host"><titleInfo><title>Journal of Clinical Psychopharmacology</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>263</start><end>269</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit39"><titleInfo><title>Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ono</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Hatanaka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Hotta</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Tsutsui</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Satoh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FJ</namePart><namePart type="family">Gonzalez</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ (1995) Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics, 5, 143–150.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>143</start><end>150</end></extent></part><relatedItem type="host"><titleInfo><title>Pharmacogenetics</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>143</start><end>150</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit40"><titleInfo><title>Contribution of human CYP3A subfamily members to the 6‐hydroxylation of chlorzoxazone</title></titleInfo><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Gorski</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DR</namePart><namePart type="family">Jones</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SA</namePart><namePart type="family">Wrighton</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SD</namePart><namePart type="family">Hall</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gorski JC, Jones DR, Wrighton SA, Hall SD (1997) Contribution of human CYP3A subfamily members to the 6‐hydroxylation of chlorzoxazone. Xenobiotica, 27, 243–256.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>243</start><end>256</end></extent></part><relatedItem type="host"><titleInfo><title>Xenobiotica</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>243</start><end>256</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit41"><titleInfo><title>Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans</title></titleInfo><name type="personal"><namePart type="given">VM</namePart><namePart type="family">Mishin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AS</namePart><namePart type="family">Rosman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Basu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Kessova</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Oneta</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CS</namePart><namePart type="family">Lieber</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mishin VM, Rosman AS, Basu P, Kessova I, Oneta CM, Lieber CS (1998) Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans. American Journal of Gastroenterology, 93, 2154–2161.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>2154</start><end>2161</end></extent></part><relatedItem type="host"><titleInfo><title>American Journal of Gastroenterology</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>2154</start><end>2161</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit42"><titleInfo><title>Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method</title></titleInfo><name type="personal"><namePart type="given">V</namePart><namePart type="family">Ozdemir</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Kalowa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BK</namePart><namePart type="family">Tang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AD</namePart><namePart type="family">Paterson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SE</namePart><namePart type="family">Walker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Endrenyi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AD</namePart><namePart type="family">Kashuba</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics, 10, 373–388.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>373</start><end>388</end></extent></part><relatedItem type="host"><titleInfo><title>Pharmacogenetics</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>373</start><end>388</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit43"><titleInfo><title>Identification of a polymorphically expressed member of the human cytochrome P‐450III family</title></titleInfo><name type="personal"><namePart type="given">SA</namePart><namePart type="family">Wrighton</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BJ</namePart><namePart type="family">Ring</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PB</namePart><namePart type="family">Watkins</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">VandenBranden</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wrighton SA, Ring BJ, Watkins PB, VandenBranden M (1989) Identification of a polymorphically expressed member of the human cytochrome P‐450III family. Molecular Pharmacology, 36, 97–105.</note><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>97</start><end>105</end></extent></part><relatedItem type="host"><titleInfo><title>Molecular Pharmacology</title></titleInfo><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>97</start><end>105</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit44"><titleInfo><title>First‐pass metabolism of cyclosporin by the gut</title></titleInfo><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Kolars</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WM</namePart><namePart type="family">Awni</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RM</namePart><namePart type="family">Merion</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PB</namePart><namePart type="family">Watkins</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kolars JC, Awni WM, Merion RM, Watkins PB (1991) First‐pass metabolism of cyclosporin by the gut. Lancet, 338, 1488–1490.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>338</number></detail><extent unit="pages"><start>1488</start><end>1490</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>338</number></detail><extent unit="pages"><start>1488</start><end>1490</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit45"><titleInfo><title>Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter‐ and intraindividual hepatic CYP3A variability after liver transplantation</title></titleInfo><name type="personal"><namePart type="given">KE</namePart><namePart type="family">Thummel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DD</namePart><namePart type="family">Shen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TD</namePart><namePart type="family">Podoll</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Thummel KE, Shen DD, Podoll TD et al. (1994) Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter‐ and intraindividual hepatic CYP3A variability after liver transplantation. Journal of Pharmacology and Experimental Therapeutics, 271, 557–566.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>271</number></detail><extent unit="pages"><start>557</start><end>566</end></extent></part><relatedItem type="host"><titleInfo><title>Journal of Pharmacology and Experimental Therapeutics</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>271</number></detail><extent unit="pages"><start>557</start><end>566</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit46"><titleInfo><title>Use of midazolam as a human cytochrome P450 3A probe: I. In vitro‐ in vivo correlations in liver transplant patients</title></titleInfo><name type="personal"><namePart type="given">KE</namePart><namePart type="family">Thummel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DD</namePart><namePart type="family">Shen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TD</namePart><namePart type="family">Podoll</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Thummel KE, Shen DD, Podoll TD et al. (1994) Use of midazolam as a human cytochrome P450 3A probe: I. In vitro‐ in vivo correlations in liver transplant patients. Journal of Pharmacology and Experimental Therapeutics, 271, 549–556.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>271</number></detail><extent unit="pages"><start>549</start><end>556</end></extent></part><relatedItem type="host"><titleInfo><title>Journal of Pharmacology and Experimental Therapeutics</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>271</number></detail><extent unit="pages"><start>549</start><end>556</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit47"><titleInfo><title>The erythromycin breath test predicts the clearance of midazolam</title></titleInfo><name type="personal"><namePart type="given">KS</namePart><namePart type="family">Lown</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KE</namePart><namePart type="family">Thummel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PE</namePart><namePart type="family">Benedict</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DD</namePart><namePart type="family">Shen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DK</namePart><namePart type="family">Turgeon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Berent</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PB</namePart><namePart type="family">Watkins</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, Watkins PB (1995) The erythromycin breath test predicts the clearance of midazolam. Clinical Pharmacology and Therapeutics, 57, 16–24.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>16</start><end>24</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>16</start><end>24</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit48"><titleInfo><title>Optimal plasma sampling to predict AUC of the CYP3A probe midazolam</title></titleInfo><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Kim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AD</namePart><namePart type="family">Kashuba</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AN</namePart><namePart type="family">Nafziger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kim JS, Kashuba AD, Nafziger AN et al. (1999) Optimal plasma sampling to predict AUC of the CYP3A probe midazolam. Clinical Pharmacology and Therapeutics, 65, 185.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>185</start></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>185</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit49"><titleInfo><title>The disposition of dapsone in cirrhosis</title></titleInfo><name type="personal"><namePart type="given">DG</namePart><namePart type="family">May</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PA</namePart><namePart type="family">Arns</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WO</namePart><namePart type="family">Richards</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">May DG, Arns PA, Richards WO et al. (1992) The disposition of dapsone in cirrhosis. Clinical Pharmacology and Therapeutics, 51, 689–700.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>689</start><end>700</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>689</start><end>700</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit50"><titleInfo><title>Urinary excretion of 6 beta‐hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations</title></titleInfo><name type="personal"><namePart type="given">SJ</namePart><namePart type="family">Kovacs</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DE</namePart><namePart type="family">Martin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DE</namePart><namePart type="family">Everitt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SD</namePart><namePart type="family">Patterson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DK</namePart><namePart type="family">Jorkasky</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK (1998) Urinary excretion of 6 beta‐hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clinical Pharmacology and Therapeutics, 63, 617–622.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>617</start><end>622</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>617</start><end>622</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit51"><titleInfo><title>Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol</title></titleInfo><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Hunt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PB</namePart><namePart type="family">Watkins</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Saenger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hunt CM, Watkins PB, Saenger P et al. (1992) Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clinical Pharmacology and Therapeutics, 51, 18–23.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>18</start><end>23</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>18</start><end>23</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit52"><titleInfo><title>Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men</title></titleInfo><name type="personal"><namePart type="given">MT</namePart><namePart type="family">Kinirons</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">O'Shea</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TE</namePart><namePart type="family">Downing</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kinirons MT, O'Shea D, Downing TE et al. (1993) Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clinical Pharmacology and Therapeutics, 54, 621–629.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>621</start><end>629</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>621</start><end>629</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit53"><titleInfo><title>N‐Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity</title></titleInfo><name type="personal"><namePart type="given">HJ</namePart><namePart type="family">Gill</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MD</namePart><namePart type="family">Tingle</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BK</namePart><namePart type="family">Park</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gill HJ, Tingle MD, Park BK (1995) N‐Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. British Journal of Clinical Pharmacology, 40, 531–538.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>531</start><end>538</end></extent></part><relatedItem type="host"><titleInfo><title>British Journal of Clinical Pharmacology</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>531</start><end>538</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit54"><titleInfo><title>Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Schmider</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Greenblatt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SM</namePart><namePart type="family">Fogelman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LL</namePart><namePart type="family">von Moltke</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RI</namePart><namePart type="family">Shader</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL, Shader RI (1997) Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharmaceutics & Drug Disposition, 18, 227–240.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>227</start><end>240</end></extent></part><relatedItem type="host"><titleInfo><title>Biopharmaceutics & Drug Disposition</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>227</start><end>240</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit55"><titleInfo><title>Update: genetic polymorphism of drug metabolizing enzymes in humans</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Tanaka</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tanaka E (1999) Update: genetic polymorphism of drug metabolizing enzymes in humans. Journal of Clinical Pharmacology and Therapeutics, 24, 323–329.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>323</start><end>329</end></extent></part><relatedItem type="host"><titleInfo><title>Journal of Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>323</start><end>329</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit56"><titleInfo><title>Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva</title></titleInfo><name type="personal"><namePart type="given">U</namePart><namePart type="family">Fuhr</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KL</namePart><namePart type="family">Rost</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fuhr U, Rost KL (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics, 4, 109–116.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>109</start><end>116</end></extent></part><relatedItem type="host"><titleInfo><title>Pharmacogenetics</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>109</start><end>116</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit57"><titleInfo><title>The paraxanthine: caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained?</title></titleInfo><name type="personal"><namePart type="given">O</namePart><namePart type="family">Spigset</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Hagg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Soderstrom</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Dahlqvist</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Spigset O, Hagg S, Soderstrom E, Dahlqvist R (1999) The paraxanthine: caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics, 9, 409–412.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>409</start><end>412</end></extent></part><relatedItem type="host"><titleInfo><title>Pharmacogenetics</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>409</start><end>412</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit58"><titleInfo><title>Estimation of cytochrome P‐450 CYP1A2 activity in 863 healthy Caucasians using a saliva‐based caffeine test</title></titleInfo><name type="personal"><namePart type="given">I</namePart><namePart type="family">Tantcheva‐Poor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Zaigler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Rietbrock</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U</namePart><namePart type="family">Fuhr</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tantcheva‐Poor I, Zaigler M, Rietbrock S, Fuhr U (1999) Estimation of cytochrome P‐450 CYP1A2 activity in 863 healthy Caucasians using a saliva‐based caffeine test. Pharmacogenetics, 9, 131–144.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>131</start><end>144</end></extent></part><relatedItem type="host"><titleInfo><title>Pharmacogenetics</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>131</start><end>144</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit59"><titleInfo><title>Salivary analysis for determination of dextromethorphan metabolic phenotype</title></titleInfo><name type="personal"><namePart type="given">ZY</namePart><namePart type="family">Hou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LW</namePart><namePart type="family">Pickle</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PS</namePart><namePart type="family">Meyer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RL</namePart><namePart type="family">Woosley</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hou ZY, Pickle LW, Meyer PS, Woosley RL (1991) Salivary analysis for determination of dextromethorphan metabolic phenotype. Clinical Pharmacology and Therapeutics, 49, 410–419.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>410</start><end>419</end></extent></part><relatedItem type="host"><titleInfo><title>Clinical Pharmacology and Therapeutics</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>410</start><end>419</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit60"><titleInfo><title>A method for the simultaneous evaluation of the activities of seven major human drug‐metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry</title></titleInfo><name type="personal"><namePart type="given">EA</namePart><namePart type="family">Dierks</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KR</namePart><namePart type="family">Stams</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HK</namePart><namePart type="family">Lim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Cornelius</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SE</namePart><namePart type="family">Ball</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE (2001) A method for the simultaneous evaluation of the activities of seven major human drug‐metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metabolism and Disposition, 29, 23–29.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>23</start><end>29</end></extent></part><relatedItem type="host"><titleInfo><title>Drug Metabolism and Disposition</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>23</start><end>29</end></extent></part></relatedItem></relatedItem><identifier type="istex">57DB5EBEAF56F5D9895376010054E89897264292</identifier><identifier type="ark">ark:/67375/WNG-LXBFBDF7-9</identifier><identifier type="DOI">10.1046/j.1365-2710.2003.00486.x</identifier><identifier type="ArticleID">JCPT486</identifier><accessCondition type="use and reproduction" contentType="copyright">© Wiley. All rights reserved.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-15</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-LXBFBDF7-9/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002387 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002387 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:57DB5EBEAF56F5D9895376010054E89897264292
|texte= How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
}}
| This area was generated with Dilib version V0.6.33. |  |